Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 3/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | FABP3 | P05413 | 1/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30650456 | 0.84 | S1PR1 (0.80) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL30653896 | 0.84 | S1PR1 (0.80) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL30649426 | 0.84 | S1PR1 (0.80) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL13271118 | 0.84 | FABP3 (0.64) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22798172 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22798380 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22798379 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22798411 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL22798410 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL18932079 | 0.83 | S1PR1 (0.79) | S1PR1PRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8657943-B2 | 1-hydroxy-2-O-acyl-sn-glycero-3-phosphocholine compounds, preparation process, antifouling composition, process for its preparation, method to prevent fouling, method to turn a surface into an antifouling surface, and, covered surface | UFRJ, IEAPM, UFF (BR) | 2014-02-25 | — | — | US | disclosed |
| US-8657943-B2 | 1-hydroxy-2-O-acyl-sn-glycero-3-phosphocholine compounds, preparation process, antifouling composition, process for its preparation, method to prevent fouling, method to turn a surface into an antifouling surface, and, covered surface | UFRJ, IEAPM, UFF (BR) | 2014-02-25 | — | — | US | disclosed |
| US-20120135134-A1 | 1-HYDROXY-2-O-ACYL-SN-GLYCERO-3-PHOSPHOCHOLINE COMPOUNDS, PREPARATION PROCESS, ANTIFOULING COMPOSITION, PROCESS FOR ITS PREPARATION, METHOD TO PREVENT FOULING, METHOD TO TURN A SURFACE INTO AN ANTIFOULING SURFACE, AND, COVERED SURFACE | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO - UFRJ (BR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135134-A1 | 1-HYDROXY-2-O-ACYL-SN-GLYCERO-3-PHOSPHOCHOLINE COMPOUNDS, PREPARATION PROCESS, ANTIFOULING COMPOSITION, PROCESS FOR ITS PREPARATION, METHOD TO PREVENT FOULING, METHOD TO TURN A SURFACE INTO AN ANTIFOULING SURFACE, AND, COVERED SURFACE | PHOSPHO1, MBOAT1, ABHD5 | S1PR1 559/4885PRKCA 1754/4885PRKCE 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.